STAT3 and lung carcinoma: In this study, we define a novel pathway by which cellular sensitivity to paclitaxel is regulated by miR-337-3p and its two direct regulatory targets, STAT3 and RAP1A. We have shown that miR-337-3p sensitizes lung cancer cell lines to paclitaxel treatment by directly down-regulating the expression of STAT3 and RAP1A, leading to increased cell death by enhancing the paclitaxel-induced arrest of cells in the G2/M phase of the cell cycle.